Recent Updates
Recently added Catalysts
GH Positive Sentiment

Guardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Thursday, November 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Guardant Health reported a total revenue of $361.0 million for Q3 2026, marking a 36% increase from Q3 2025. The oncology segment contributed $231.3 million, reflecting a 25% growth. Additionally, the company performed 117,000 oncology tests, which is a 58% rise compared to the previous year. The company has also increased its revenue guidance for 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Total revenue increased by 36% year-over-year.
  • Oncology revenue grew by 25%, indicating strong demand.
  • 117,000 oncology tests performed, up by 58%.

Full Press Release Details

PALO ALTO, Calif.--(BUSINESS WIRE)---- $GH--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights For the three-month period ended September 30, 2026, as compared to the same period of 2025: Reported total revenue of $361.0 million, an increase of 36%, driven by: Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58% Bioph

Frequently Asked Questions

What was Guardant Health's total revenue for Q3 2026?

Guardant Health reported a total revenue of $361.0 million.

How much did oncology revenue increase?

Oncology revenue increased by 25% to $231.3 million.

How many oncology tests were performed?

The company performed 117,000 oncology tests, up 58%.

Did Guardant Health raise its revenue guidance?

Yes, Guardant Health increased its revenue guidance for 2026.

ShareAdd on Google
Tags: GH Guardant Health oncology financial results 2026 revenue guidance
Last updated: Nov 5, 2026

Biotech snapshot

Cash runway
$1027M liquidity · $8M/mo burn
~130 mo
Minimal dilution risk